Compare Inovio Pharmaceuticals Inc (INO) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while YieldMax TSLA Option Income Strategy ETF trades at $25.79. Which is the better fit depends on your goals.
| INO | TSLY | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $2.87 | $48.25 |
52-Week Low | $1.05 | $25.07 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
TSLY trades at $25.07, down 2.57% over the past day, with a bearish technical outlook from moving averages and oscillators. The ETF maintains a high distribution yield, with weekly dividends averaging around $0.30 per share, though recent news highlights concerns about capped upside relative to Tesla's performance. Key support sits near $25, while resistance is at $26.
The outlook for TSLY is cautious due to its option income strategy limiting capital appreciation. Risks include volatility from Tesla's stock movements and potential erosion of principal from return of capital distributions. Investors seeking high yield may find value, but must weigh the trade-off between income and growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
